Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 10 Billion Datapoints – Significantly Enhancing Precision Medicine Capabilities & Expanding Potential for Biopharma Collaborations and Partnerships
- Represents a 10-fold increase in the number of datapoints from one year ago, November 2020, and a 37-fold increase since the June 2020 IPO
- Accelerates the discovery of new indications for Lantern's existing drug candidates, as well as the identification of new drug candidates and combination therapies
- Data growth was largest in bladder, pancreatic, brain and blood cancers
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.